New trial
Phase I/II Study: AZD4360 in CLDN18.2-Positive Advanced Solid Tumors
- Trial ID
- NCT06921928 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 6 Locations
- Published in
- New in Oncology - May 14, 2025
AstraZeneca is evaluating AZD4360—a CLDN18.2 and CD3 directed bispecific antibody—as monotherapy in adult patients with locally advanced or metastatic solid tumors (gastric/GEJ, biliary tract, and PDAC) that express CLDN18.2, with an emphasis on safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings